iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/15592724
Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Nov;251(11):1297-303.
doi: 10.1007/s00415-004-0619-5.

Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis

Helen Tremlett  1 , Joel Oger
Affiliations
Review

Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis

Helen Tremlett et al. J Neurol. 2004 Nov.

Abstract

This review explores the salient issues surrounding liver injury and liver monitoring associated with beta-interferon (IFNB) treatment for multiple sclerosis (MS). Post-marketing studies have found a higher proportion of IFNB-treated MS patients with elevated aminotransferases than reported in the pivotal clinical trials. Although the risk of severe liver injury appears small, the true incidence is unknown. Post-marketing studies have shown that the greatest period of risk for the development of liver test abnormalities appears to be in the first year of IFNB treatment. The risk also increases with the more frequently administered, higher-dosage IFNBs. Males are more likely than females to develop elevated aminotransferases (> upper normal limit), although females appear at a greater risk of severe liver injury. Of the commonly used biochemical liver tests, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP) and bilirubin appear the most useful for routine monitoring of IFNB treatment. Whilst many other factors can affect liver test results, including obesity, alcohol, concomitant medications, co-morbidities and theoretically even MS itself, regular liver testing both prior and during IFNB therapy might help minimise Type A or dose/frequency dependent aminotransferase elevations. However, testing will probably not prevent the Type B idiosyncratic reactions which can result in severe hepatic injury; hence patients need to be aware, and to report hepatic side effects promptly.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. J Gastroenterol. 2002;37(8):617-25 - PubMed
    1. Am J Gastroenterol. 1996 Oct;91(10 ):2233-4 - PubMed
    1. Ann Neurol. 1996 Mar;39(3):285-94 - PubMed
    1. Semin Oncol. 1992 Oct;19(5):551-65 - PubMed
    1. J Clin Pharm Ther. 2001 Dec;26(6):437-44 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources